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Abstract
Background: To illustrate that Breast-MRI performed in high spatial resolution and low temporal resolution
(1 minute) allows the measurement of kinetic parameters that can assess the final pathologic response to
neoadjuvant chemotherapy in breast cancer.
Methods: Breast-MRI was performed in 24 women before and after treatment. Eight series of 1.11 minute-duration
were acquired with a sub-millimeter spatial resolution. Transfer constant (K
trans) and leakage space (Ve) were
calculated using measured and theoretical Arterial Input Function (AIF). Changes in kinetic parameters after
treatment obtained with both AIFs were compared with final pathologic response graded in non-responder (<
50% therapeutic effect), partial-responder (> 50% therapeutic effect) and complete responder. Accuracies to identify
non-responders were compared with receiver operating characteristic curves.
Results: With measured-AIF, changes in kinetic parameters measured after treatment were in agreement with the
final pathological response. Changes in Ve and K
trans were significantly different between non-(N = 11), partial-(N =
7), and complete (N = 6) responders, (P = 0.0092 and P = 0.0398 respectively). A decrease in Ve of more than -72%
and more than -84% for K
trans resulted in 73% sensitivity for identifying non-responders (specificity 92% and 77%
respectively). A decrease in Ve of more than -87% helped to identify complete responders (Sensitivity 89%,
Specificity 83%). With theoretical-AIF, changes in kinetic parameters had lower accuracy.
Conclusion: There is a good agreement between pathological findings and changes in kinetic parameters
obtained with breast-MRI in high spatial and low temporal resolution when measured-AIF is used. Further studies
are necessary to confirm whether MRI contrast kinetic parameters can be used earlier as a response predictor to
neoadjuvant chemotherapy.
Background
Neoadjuvant chemotherapy is increasingly used in breast
cancer patients to decrease the tumour size in large can-
cers to enable breast-conserving treatment. Accurate eva-
luation of the treatment response before surgery offers
the potential to avoid unnecessary mutilating procedures
in patients with a favorable prognosis, without jeopardiz-
ing local control or long-term survival. Compared with
physical examination, and conventional modalities (US
and mammography), breast MRI appears to be the best
monitoring method for neoadjuvant chemotherapy [1,2].
Although MR imaging may be superior to other methods
[3,4], the correlation between conventional anatomic
MRI analysis and histopathological response is not per-
fect [5]. The determination of residual tumour size is
underestimated and unreliable in carcinomas significantly
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detections in up to 30% of patients [6]. There is now
increasing evidence that functional analysis of the micro-
circulation by using dynamic contrast material-enhanced
MR imaging could be used to identify responders and
non-responders during and/or after neoadjuvant che-
motherapy more reliably than conventional anatomic
MRI results alone [6-10]. The functional analysis is based
on post-therapeutic changes of microvessels permeability,
tissue perfusion, blood volume, and extracellular leakage
space. These parameters can be obtained by analyzing
the enhancement kinetics measured in the tissue of inter-
est and in its afferent artery (Arterial Input Function,
AIF) using compartmental modeling [11,12].
Several compartmental models can be chosen for assess-
ment. The simplest model, applied to MRI data by both
Larsson et al. [13] and Tofts and Kermode [14] allows cal-
culation of the transfer constant (K
trans) that reflects
simultaneously perfusion and permeability, and the leak-
age space (Ve). More recent models potentially enable to
distinguish perfusion and permeability separately [15-18].
The choice of the model and kinetic parameters to be cal-
culated depends on the acquisition parameters. In particu-
lar, the temporal resolution determines whether the
vascular component can be taken into account. Indeed,
perfusion and blood volume measurement requires a high
temporal resolution, because the sampling interval must
be less than the mean transit time of the contrast agent
[19], which is usually less than 2 seconds [20]. In breast
MRI, high spatial resolution is required because most of
the diagnostic criteria are based on lesion morphology
[21]. Due to technical reasons in most current systems of
magnetic field up to 1.5T, the 3D high spatial resolution
limits the temporal resolution to as low as 1 minute and
imposes to use the simplest model limited to the estima-
tion of K
trans and Ve values [22-24].
The estimation of the kinetic parameters requires two
sets of data: the variation of contrast concentration in
time in the tissue of interest and in the feeding artery
(arterial input function, AIF). In MRI, concentrations can
be non-invasively derived from signal intensity. In Breast
MRI, the measurement of the AIF can be difficult. A
large blood vessel such as the aorta is rarely included in
the field of view [25] and the measurements of the inter-
nal thoracic artery can be difficult due to its small size
with the risk of partial volume artifact [26]. For these rea-
sons, several authors use a calculated theoretical AIF [7].
The time curve of contrast agent concentration in the
plasma is represented by a biexponential decay based on
the AIF measured by Weinmann et al [27]. However, the
use of a calculated theoretical AIF may entail errors in
MR estimates of kinetic parameters.
The purpose of this retrospective study is to demon-
strate that even with low temporal resolution routine
MRI protocol, changes in microcirculation kinetic para-
meters such as K
trans and Ve can be used to determine
tumor response to neoadjuvant chemotherapy in breast
cancer as observed at the final pathological evaluation
after surgery.
Methods
Demography
This study was part of the Remagus [28,29] protocol,
approved by the ethics committee, and requiring informed
consent before enrollment from all patients. Three physi-
cians specialized in breast cancer with over 10 years of
experience performed the patients follow up and deter-
mined the clinical response to neoadjuvant chemotherapy
according the WHO criteria. The Remagus protocol was a
neoadjuvant chemotherapy trial for locally advanced breast
cancers including 4 cycles of Antracycline and Cyclopho-
sphamide, followed by 4 cycles of Docetaxel chemother-
apy. Patients with noninflammatory, stage II to III breast
cancer were included during 12 month. Diagnosis of inva-
sive breast carcinoma was made by core needle biopsy in
all patients. Surgery was performed less than 4 weeks after
the last course of chemotherapy. Patients either underwent
mastectomy or wide local excision with axillary lymph
node dissection.
Pathologic Assessment
One senior pathologist with 20 years of experience in
breast pathology blinded to the MRI results assessed
tumor response and graded according to the scale estab-
lished by Sataloff [30] as shown Table 1: total or near-total
therapeutic effect (grade A), more than 50% therapeutic
effect but less than total or near-total effect (grade B), less
than 50% therapeutic effect but visible effect (grade C), or
no therapeutic effect (grade D). Pathologic tumor regres-
sion was used as the gold standard to evaluate treatment
response. For comparison with imaging five groups of
patients were defined according to the response grade:
complete responder group (grade A), partial responder
group (grade B), responder group (A+B), non-responder
group (grade C+D), and non-complete responders (grades
B+C+D).
Table 1 Tumor response graded according to the scale
established by Sataloff
Sataloff
Grade
Therapeutic effect at pathology
A Total or near-total
B More than 50% therapeutic effect but less than total or
near-total effect
C Less than 50% therapeutic effect but visible effect
D No therapeutic effect
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All patients underwent two breast MRI, the first exam less
than 1 week before the beginning of the treatment and the
second MRI performed after completion of chemotherapy
treatment and less than 2 weeks before surgery. All MRI
were performed on a 1.5 Tesla Siemens Symphony TIM
MR system (Erlangen, Germany), with a breast-specific
coil with four elements, CP Breast Array Coil. DCE-MRI
was acquired with a 3D T1-weighted gradient echo
sequence using a TR of 4.67 ms, a TE of 1.65 ms and a
flip angle of 12°. The DCE-MRI sequences (120 contigu-
ous 1.2-mm-thick slices, 320 × 280 mm FOV, 380 ×
300 matrix, 1.11 min scan duration, axial slices on both
breasts) were acquired at 0, 1.36, 2.47, 3.59, 5.10, 6.21,
7.32, and 8.44 min. The contrast agent, gadoterate dime-
glumine (Dotarem
®, Guerbet, France), was injected imme-
diately after the acquisition of the first DCE-MRI
sequence with an automatic injector (Spectris, Medrad,
UK) at a dose of 0.1 mmol/Kg with a rate of 2 ml/sec and
pushed by saline serum. The minimum delay between the
end of the contrast injection and the beginning of next
sequence acquisition was 20 second.
Data processing
A senior and a junior radiologist with 8 years and 2 years
of experience in breast imaging respectively, performed
all image analysis. Tumor sizes were measured with elec-
tronic calipers on high-resolution T1 weighted post con-
trast images (measured on the 90-120 second subtraction
image), following the WHO methodology, the same day
of the exam by the same radiologist as required by the
clinical protocol [31], the functional analysis was per-
formed retrospectively by the same radiologists. For this
analysis, the use of a 3D acquisition for the DCE-MRI
allowed the selection of region of interest (ROI) at a dif-
ferent level for tumor than for internal thoracic artery
when necessary. Regions of interest were drawn by the
radiologist on subtraction images with an appropriate
window and magnification factor to optimize the detec-
tion of both enhancing tumor margin and internal thor-
acic artery. For the AIF, the center of the ROIs were
manually defined in the center of the internal thoracic
artery in the native images at the second acquisition time
(first acquisition after injection), and the 8 surrounding
pixels were automatically selected by the computer. This
9 pixel square was automatically reproduced at the same
position at all acquisition time. Then, each ROI was
manually translated when necessary for motion artifacts
correction to avoid partial volume artifacts. The tumor
ROIs were placed around the edge of the anatomically
defined tumor but away from non-enhancing areas which
were either necrotic or so poorly perfused that they
could not be evaluated in functional imaging.
With the 3D T1-weighted gradient echo sequence use
for the DCE-MRI, the contrast information was recorded
30 seconds after the beginning of the acquisition and at
least 50 second after the injection. Thus, we assumed
that the contrast information was measured after the first
pass of the bolus of contrast media in the artery and
therefore after the peak concentration [32]. Hence, for all
patients, contrast media concentrations in artery and
tumor were supposed to be low (< 2 mM Gd-DOTA)
and a linear relationship was assumed between signal
intensity kinetics measured in ROIs and contrast media
concentrations according with the following equations:
Ct (t) = R · (ISt (t) − ISt (0)) (1)
Cp (t) = R ·

ISp (t) − ISp (0)

(2)
Where Ct and Cp are the concentrations of contrast
media in the tissue of interest and plasma, respectively.
ISt and ISp are the signal intensities measured with the
R O I si nt h et i s s u eo fi n t e r e s t and the internal thoracic
artery, respectively. R is an amplitude constant, which is
simplified in equation 3.
Custom software [33] written with Matlab
® (Math-
Works Inc., Natick, MA, USA) was used to calculate
kinetic parameters. These parameters included the
transfer constant, K
trans (min
-1), of gadolinium-based
contrast agent between blood plasma and the extravas-
cular extracellular space (EES), and the EES fractional
volume, Ve (%). Parameters were adjusted using the
modified Kety model applied to MRI data by both Lars-
son et al [13] and Tofts and Kermode [34] and fully
described recently by various authors such as Buckley
[19] or Padhani [7]:
Ct (t) = Ktrans ·
 t
0
Cp(u)·exp

−
Ktrans
Ve
· (t − u)

· du (3)
This model assumes that the plasma volume is negligi-
ble. It also assumes that a short bolus injection time is
used, with instant mixing and fast exchanges of all mobile
protons within the tissue. A pixel by pixel analysis was
used given a K
trans and a Ve maps. For all exams, para-
meters were adjusted twice: with a Cp obtained directly
from the measured AIF (ROIs selecting the internal thor-
acic artery); with a Cp related to a calculated theoretical
AIF. The theoretical AIF was modeled by using a biexpo-
nential decay that corresponds to the results measured
by Weinmann et al [27]:
Cp (t) = D ·

a1 · e−m1·t + a2 · e−m2·t
(4)
Where D is the injected dose of contrast agent (in
millimoles per liter per kilogram of body weight), a1 =
3.99 kg/L and a2 = 4.78 kg/L are two amplitude
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-1 and m2 = 0.0111 min
-1 are
two rate constants [27].
Statistical analysis
The kinetic parameter changes measured after treatment
in each group of patients defined by final pathologic find-
ings were compared using non parametric tests (Mann-
Whitney U test for two independent random samples and
Kruskal-Wallis test for three independent random sam-
ples). Kinetic parameter changes of responder patients
were compared to the changes of the non-responder
patients. Kinetic parameter changes after treatment were
compared between complete-, partial-, and non-responder
patients. Eventually, the ability of the technique to distin-
guish the complete responders was tested. All compari-
sons were performed twice: once with kinetic parameters
obtained with measured AIF and then with kinetic para-
meters estimated with theoretical AIF. The differences in
tumour size changes between groups of patients were also
compared with nonparametric methods.
Receiver operating characteristic (ROC) analyses of
transfer constant and EES fractional volume changes
were used to select threshold for the identification of
responder and non-responder patients. The diagnostic
performance of changes in parameters obtained with a
measured or a theoretical AIF were compared by using
the approach of DeLong et Clarke-Pearson [35].
Results were analyzed using a statistical software pack-
age (Analyse-it Software, Leeds, UK) with an a level set at
5%. All results are given with a 95% confidence interval
(95% CI).
Breast tumours size changes in MRI have an accuracy
varying from 25% to 93% in detecting tumor response
after neoadjuvant chemotherapy [6,29-31]. We estimate
that our approach will improve the accuracy from 55%
with tumor size changes to 80% using kinetic parameter
changes. Thus, sample size of 24 patients was computed
to provide 90% power at the overall 5% (two-sided) signifi-
cance level to detect an accuracy of 80% [32].
Results
Patients and Pathologic Response
Patient and tumor characteristics are listed in Table 2.
After completion of chemotherapy, within the 24 included
patients a Sataloff grade A response was identified in 6
patients, a grade B response was identified in 7 patients,
and a grade C+D was identified in 11 patients.
Using a conventional cutoff value of a decrease of 50%
(WHO criteria) of tumor size after treatment compared
to baseline, the sensitivity, specificity, positive and nega-
tive predictive values, and accuracy of physical examina-
tion to detect non-responder were respectively 13% (95%
CI:0.8%,54%), 82% (95% CI:48%,97%), 33%, 56% and 53%.
The performances of conventional anatomic MRI were
27% (95% CI:6%,61%), 77% (95% CI:46%,95%), 50%, 56%
and 54%. Physical examination and conventional mor-
phological MRI based on size measurement were not
correlated with the pathologic response after chemother-
apy (Mann-Whitney U test, P = 0.44 and P = 0.42
respectively).
Interestingly, physical examination and conventional
morphological MRI were more accurate for the detection
of complete responders when compared with theirs ability
to detect non-responders, (Sensitivity, Specificity, Positive
Predictive Value, Negative Predictive Value, and accuracy
of 85% (95% CI:54%,97%), 67% (95% CI:24%,94%), 85%,
67%, and 79% with the physical exam and 67% (95%
CI:41%,87%), 83% (95% CI:36%,100%), 92%, 45% and 71%
respectively in MRI). Physical examination was better
correlated with the final pathological response than con-
ventional morphological MRI in detecting complete
responders (Mann-Whitney U test, P = 0.05 and P = 0.22
respectively).
Evaluation of the neoadjuvant chemotherapy in DCE-MRI
The selection and measurement of the internal thoracic
artery was possible in all patients (N = 24). Changes in
kinetic parameters after the last course of chemotherapy
were obtained using measured and theoretical AIF.
With measured AIF
Under treatment, changes in K
trans and Ve were signifi-
cantly different between non-responders (grade C+D) and
responders (grades A+B), (Mann-Whitney U test, P = 0.01,
P < 0.01 respectively). Moreover, changes in K
trans and Ve
were significantly different between non-responders (grade
C+D), partial responders (grade B) and complete respon-
ders (grade A) as seen figure 1 (Kruskal-Wallis test,
Table 2 Patient and Tumor Characteristics (n = 24)
Characteristic Number of Patients
Age, years (mean, range) 48 (range, 31 to 62)
Tumor histology
Invasive ductal carcinoma 21
Invasive lobular carcinoma 3
Receptor status
Estrogen, (positive/negative) 17/4
Progesterone (positive/negative) 10/11
Her2/neu (positive/negative) 9/12
Scarff and Bloom Richardson grade
I 2
II 12
III 9
Stage
IIA 2
IIB 5
IIIA 7
IIIB 8
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decrease of Ve (-90% (95% CI:-97%,-80%)) was noted in
complete responders (grade A) than in non-complete
responders (grade B+C+D), (-68% (95% CI: -82%,-19%);
Mann-Whitney U test, P < 0.01). All results are summar-
ized Table 3 and 4.
With theoretical AIF
Ve changes were found to be different between non-
responders (grade, C+D) and responders (grades, A+B),
(Mann-Whitney U test, P = 0.05). However, no significant
difference was found between patient groups with K
trans.
Typical examples of complete responder (#22) and
non-responder (#10) patients are given in figure 2 and 3.
Identification of responders and non-responders
After treatment, a reduction of less than -84% in trans-
fer constant (K
trans) with measured AIF, would have had
a 73% (95% CI:39%,94%) sensitivity in the identification
of 8 of 11 non-responders patients (i.e., pathologic sub-
g r o u pC + D )a n dw o u l dh a v ee x c l u d e d3o u to f1 3
responders (specificity 77% (95% CI:46%,95%), positive
predictive value 73%, negative predictive value 77%,
accuracy 75%, area under ROC curve 0.80 (95 CI:
0.62,0.99)). With a theoretical AIF to assess K
trans,t h e
cutoff (-85%) had lower accuracy (sensitivity 46% (95%
CI:167%,76%), specificity 54% (95% CI:25%,80%), positive
predictive value 46%, negative predictive value 54%,
accuracy 50%, area under ROC curve 0.48 (95% CI:
24%,73%)). However, the difference between areas under
ROC curves of K
trans obtained with measured and theo-
retical AIF (Figure 4) was not significantly different
(Clarke-Pearson test, P = 0.1475).
A reduction of less than -72% in leakage space (Ve)
with measured AIF, would have enabled identification of
8 of eleven non-responders (sensitivity 73% (95%
CI:39%,94%)) and would have excluded only 1 out of 13
responders (specificity 92% (95% CI:64%,100%)), positive
predictive value 89%, negative predictive value 80%,
accuracy 83%, area under ROC curve 0.83 (95% CI:
64%,100%)). With a theoretical AIF to assess Ve, the cut-
off (-51%) had lower accuracy (sensitivity 64% (95%
CI:31%,89%), specificity 100% (95% CI:75%,100%), posi-
tive predictive value 100%, negative predictive value
77%, accuracy 83%, area under ROC curve 0.74 (95%
CI:51%,97%)). However, the difference between areas
under ROC curves of Ve obtained with measured and
theoretical AIF (Figure 4) was not significantly different
(Clarke-Pearson test, P = 0.3216). Moreover, a reduction
of less than -87% in Ve with measured AIF, would have
enabled identification of 5 of 6 complete responders and
16 of 18 non complete responders (sensitivity 89% (95%
CI:65%,99%), specificity 83% (95% CI:36%,100%), positive
predictive value 94%, negative predictive value 71%,
accuracy 88%, area under the ROC curve 87% (95%
CI:71%,100%)).
T h ea c c u r a c yo ft h ec l a s s i f i c a tion between responders
and non-responders was slightly improved when K
trans
and Ve were used jointly. With a cutoff of -82% for K
trans
and -72% for Ve, all non-responders were distinguished
(sensitivity 100% (95% CI:68%,99%)), whereas 4 out of 13
responders were misdiagnosed (specificity 69% (95%
CI:39%,90%), positive predictive value 73%, negative pre-
dictive value 100%, accuracy 83%).
Discussion
This clinical study have examined the ability of conven-
tional breast DCE-MRI performed at 1.5T with high
spatial resolution (sub millimeter) and low temporal
resolution (1 acquisition per minute), to provide changes
in kinetic parameters that agree with pathological analy-
sis of response to neoadjuvant chemotherapy. Changes
in transfer constant and in leakage space obtained with
a measured AIF were significantly different between the
three pathologic response categories (Kruskal-Wallis
test, P < 0.04). We found that changes in the kinetic
parameters correlated pathologic response to neoadju-
vant chemotherapy (P < 0.04), whereas both change in
MRI-derived tumor size and final clinical examination
following neoadjuvant chemotherapy failed to correlate
with final pathologic response (Kruskal-Wallis test, P >
0.4), when complete responders and partial responders
are considered. It is well recognized that size change is
an imperfect assessment method for assessing the effects
of neoadjuvant chemotherapy. We found an appreciable
discordance between final clinical and final pathologic
response in our patient group, with almost a half of
clinical responders (13 of 24) failing to obtain a patholo-
gic response. This discrepancy between clinical and
pathologic response has been described by others. The
Figure 1 Changes (median, 1
st and 3
rd quartile and range) in
leakage space (Ve) after neoadjuvant chemotherapy in
complete responders (Sataloff grade A), partial responders
(Sataloff grade B) and non-responders (Sataloff grade C+D).
Kinetic parameters were obtained with measured AIF. The non-
responder patient that had an increase in Ve (+193%) is not shown.
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Patient # K
trans changes Ve changes Size changes Clinical Final pathologic finding
AIF theoretical AIF measured AIF theoretical AIF measured N/A Response Sataloff Grade
1 -70% -23% -73% -80% 0% PR C
2 -35% -20% -4% -52% 57% SD C
3 -2% 108% -89% -91% -100% PR C
4 -71% -22% -46% -48% -84% SD C
5 223% 166% -76% -74% -100% PR C
6 -97% -84% 23% -29% 158% PR C
7 -85% -67% -78% -64% -72% PR C
8 -93% 93% -15% -52% -99% CR C
9 -98% -98% -50% -38% -65% PR D
10 -90% -82% -50% -59% -100% PR C
11 -97% -89% -49% 193% -62% PR C
Median (C+D) -85% -23% -50% -52% -72%
95 CI [-110%,17%] [-72%,51%] [-69%,-23%] [-88%,17%] [-98%,13%]
12 -85% -95% -61% -73% -71% CR B
13 -99% -86% -65% -77% -73% PR B
14 -54% -89% -57% -48% -100% SD B
15 -94% -95% -75% -75% -33% SD B
16 65% -52% -68% -72% -100% PR B
17 -96% -84% -72% -85% -91% PR B
18 -97% -97% -77% -91% -29% PR B
Median (B) -94% -89% -68% -75% -73%
95 CI [-121%,-10%] [-100%,-71%] [-75%,-61%] [-87%,-62%] [-98%,-44%]
Median (B+C+D) -88% -83% -63% -68% -73%
95 CI [-95%,-14%] [-80%,0%] [-69%,-40%] [-82%,-19%] [-87%,-20%]
19 0% 27% -89% -89% -40% PR A
20 -15% -91% -62% -95% -99% CR A
21 4% -54% -89% -91% -100% CR A
22 -29% -98% -51% -73% -100% CR A
23 -99% -100% -95% -94% -96% CR A
24 -94% -99% -75% -87% -97% PR A
Median (A) -22% -94% -82% -90% -98%
95 CI [-87%,10%] [-122%,-16%] [-95%,-59%] [-97%,-80%] [-114%,-64%]
Final pathologic findings were graded according to the scale established by Sataloff: complete responder group (grade A), partial responder group (grade B),
responder group (A+B), and non-responder group (grade C+ D). Surgery performed after neoadjuvant chemotherapy included mastectomy or conservative
treatment or inadequate conservative surgery followed by mastectomy. SD = stable disease, PR = partial responder, CR = complete responder.
Table 4 Statistical results (P-value) of the non parametrical test (* Kruskal-Wallis and ‡ Mann-Whitney U test) used to
compare changes in the kinetic parameters, tumor size in MRI, and clinical findings, between groups of patients
defined by final pathologic findings (Sataloff Grade)
K
trans Ve Size in
MRI
Clinical
findings
Sataloff
Grade
AIF theoretical p-
value
AIF measured p-
value
AIF theoretical p-
value
AIF measured p-
value
p-value p-value
A vs B vs C
+D
0,5467 0,0398 0,0799 0,0092 0,4643 0,4643
A+B vs C+D 0,9095 0,0107 0,0474 0,0059 0,4244 0,4421
A vs B+C+D 0,3173 0,1096 0,0532 0,0077 0,2244 0,0462
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who received neoadjuvant chemotherapy, 247 achieved a
clinical Complete Response but only 88 of these had a
pathologic Complete Response.
The microvascular pressures differ from one tumor to
another depending upon the vascular architecture, vis-
cous resistance offered to blood flow and interstial fluid
diffusion [37-39]. The high interstitial fluid pressure
(IFP) seen in tumor without treatment would result in a
low diffusion of the contrast agent in the interstitial
space and hence low measured Ve value. In responder,
we can assume a decrease of the proportion of immature
vessel that yield to a reduction of the IFP and an increase
of Ve. On the other hand, tumor resistance to che-
motherapy would result in ongoing production of angio-
genic factors that maintain or increase the IFP and Ve.
We have observed that changes in kinetic parameters
obtained in low temporal resolution are more accurate
when AIF are measured instead of using a calculated the-
oretical AIF as usually performed in the literature
[20,40]. In this study, the comparison of ROC curves
obtained for K
trans changes with a measured and a theo-
retical AIF shows the inability to distinguish responders
and non-responder when a theoretical AIF is used. The
ROC curves obtained for Ve changes shows slight
improvement in performance to distinguish responders
and non-responders, not statistically significant, when
measured AIF is used. Wedam et al. have evaluated the
effect of Bevacizumab, an antiangiogenic treatment by
using the dynamic contrast enhancement MRI with theo-
retical AIF [41]. The kinetic parameters (K
trans,k ep,a n d
ve) were significantly decreased after the first cycle of
treatment. However, there was no significant difference
in any of the DCE-MRI parameters between clinical
responders and non-responders. The use of a calculated
theoretical AIF may have reduced the observed decrease
Figure 2 Images show changes in transfer constant (K
trans) in patient 22, complete responder to neoadjuvant chemotherapy (Sataloff
A). Columns show in A and D: anatomic subtraction images; in B and E: corresponding K
trans map acquired using measured Arterial Input
Function (AIF); and in C and F: corresponding K
trans map acquired using theoretical AIF. Images A, B, and C show data before neoadjuvant
chemotherapy treatment and images D, F, and G are post-treatment. After treatment a decrease of -98% is seen in K
trans using measured AIF
values and a decrease of -29% using theoretical AIF values. Note the difference between K
trans values before treatment when using measured
and theoretical AIFs. To increase visibility of the color encoded K
trans pixels the scale was reduced in postchemotherapy images.
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identification of responders. We suggest that the actual
measure of the AIF be used for the calculations of K
trans
and ve when data are obtained in low temporal
resolution.
In this study, the selection of the Arterial Input func-
tion from the internal thoracic artery was possible in all
cases, despite the risk of partial volume artifact due to
the small size of the artery [26]. The use of high spatial
resolution images helped to identify the internal thoracic
artery. Moreover, the low temporal resolution has made
possible to manually adjust ROIs on each images to
encompass motion artifact and to achieve successfully
the AIF in any of the cases. However, computed assisted
ROI selections are suitable to achieve results with a lesser
time consuming technique [42-44].
Although, the optimal temporal resolution seems to be
less than 20 seconds for tracer kinetics modeling [45-47],
several kinetic parameters studies with limited temporal
resolution obtained with the Tofts model have been
proved useful [22,48]. Li et al. have investigated the het-
erogeneity in the angiogenic response of human breast
cancer xenograft to a novel angiogenesis inhibitor. They
used the kinetic parameters provided by the Tofts and
Kermode model with data obtained in DCE-MRI with a
time resolution of 63 seconds. In their study, histogram
segmentation showed that changes in the number of vox-
els within certain segments of the transfer constant histo-
gram were the most sensitive variable for separating
control from treated tumors. Planey et al. showed good
correlation between K
trans and Ve estimates from data
acquired at 16.4-second temporal resolution compared to
33 and 64 second [49]. However, continuous technical
improvements observed in MRI, may resolve the
dilemma between the diverging demands of high tem-
poral resolution and high spatial resolution. With the
Figure 3 Images show changes in volume leakage (Ve) in patient 10 non responder to neoadjuvant chemotherapy (Sataloff grade C).
Columns show in A and D: anatomic subtraction images; in B and E: corresponding Ve map acquired using measured Arterial Input Function
(AIF); and in C and F: corresponding Ve map acquired using theoretical AIF. Images A, B, and C show data before neoadjuvant chemotherapy
treatment and images D, F, and G are post-treatment. After treatment, low decreases in Ve median were seen using the measured AIF (-59%)
and theoretical AIF (-50%) in agreement with the pathological observation. Note the disagreement with tumour size changes (-100%). To
increase visibility of the color encoded Ve pixels the scale was reduced in postchemotherapy images.
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Page 8 of 12advent of new sequences, parallel imaging and the move
to higher field strengths 3.0 a temporal resolution of 13
sec with an isotropic voxel size of 1.7 mm is feasible [50].
Also, new multichannel breast coil may help to accelerate
sequences allowing better images sampling and faster T1
mapping for an accurate signal conversion into concen-
trations. In this study, all non-responders were success-
fully classified by combining K
trans and Ve,w h e r e a st h e
separate analysis had lower sensitivity and specificity.
These results incite to obtain more parameters from
functional studies, which require faster sequences to
accurately predict tumors response to chemotherapy.
It is clear that concentration assessment improves the
final accuracy of the kinetic parameters [51]. However,
this method requires accurate measurements of the tissue
T1 relaxation time before and after contrast injection
that is usually performed in few slices due to the tem-
poral resolution constraints [52]. Nevertheless, the effect
of the native tissue T1 relaxation on signal enhancement
ratio and K
trans/Ve is very small in conditions observed in
this study: short TR < 10 ms, short TE < T2*, and low
dose of Gd-DTPA administration [22,34]. With a tem-
poral resolution of 1.11 minutes, the analysis of the AIF
was limited to the decay phase after the first pass, in this
study. Concentrations in artery was expected to be low,
and a linear relationship between concentration and sig-
nal intensity was assumed [25,32]. These assumption
seems acceptable since changes in K
trans and Ve achieved
Figure 4 ROC analysis to differentiate patients’ response to neoadjuvant chemotherapy. Using measured AIF a decrease in Ve of less than
-72% results in 73% sensitivity for identifying non-responders (specificity 92%; area 0.83). Using theoretical AIF, the cutoff value of -51% had
lower accuracy (sensitivity 64%; specificity 100%; area 0.74). For transfer constant using measured AIF, a decrease of less than -84% results in 73%
sensitivity in the identification of 8 of 11 non-responders patients (Specificity 77%; area under ROC curve 0.80). Using calculated AIF, the cutoff
value of -85% had lower accuracy (sensitivity 46%; specificity 54%; area under ROC curve 0.48).
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Page 9 of 12with measured AIF allowed to distinguish responders
from non-responders (grade, C+D) (Mann-Whitney U
test, P < = 0.01). Moreover, changes in Ve were found
helpful to distinguish complete responders from non-
complete responders (Mann-Whitney U test, P < 0.01).
And hence, a Ve change threshold may be defined to cor-
roborate breast-conserving surgery in clinical ambiguous
patients. All these technical limitations do not allow us to
measure the absolute K
trans and Ve values but only rela-
tive changes in these kinetic parameters in one tumor
between two exams. Though both K
trans and Ve changes
c o u l db eu s e dt od i f f e r e n t i a t er e s p o n d e r sa n dn o n -
responders, a few non responder patients showed an
unexpected large decrease in K
trans.T h i sc o u l db e
explained by the antivascular effects of chemotherapy
[21,53-56] that would alter the microcirculation para-
meters (K
trans) before its effects can be seen in malignant
tissue represented by Ve.
Another limitation of this preliminary study is the small
number of patients included. Larger groups of patients can
be studied by greater number of radiologists in furthers
studies as well as more kinetic parameters with advances
in medical imaging (MRI) technology. However, while
conventional breast MRI had an accuracy as low as 54%,
with a measured AIF we have reached accuracies greater
than 80% when a threshold of -72% for Ve changes or
when combined kinetic parameter changes were used in
detecting residual breast cancer after neoadjuvant che-
motherapy. The inclusion of 24 patients yielded a power
greater than 90% to evaluate the response with these
accuracies [57]. Recent studies have demonstrated the
interest of diffusion and spectroscopy data in the evalua-
tion of breast cancers response to neo adjuvant che-
motherapy [58,59]. These parameters could be combined
with kinetics parameters [8] and biological data such as
hormonal and HER2 receptors status to provide a multi-
modality comprehensive analysis.
Conclusion
This study shows that it is feasible to assess tumours’
microcirculatory kinetic parameters changes with cur-
rent breast MRI protocols used in daily clinical practice.
These changes in parameters are more accurate when
obtained using a measured AIF, and may prove helpful
to better determine breast cancer response to neoadju-
vant chemotherapy than MRI based on tumor size
measurements.
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